Cyrano Therateutics
1 known investors
Cyrano Therapeutics develops pharmaceutical therapies for long-term loss of smell and taste, conditions affecting millions of people worldwide, particularly those experiencing post-viral olfactory dysfunction. The company is advancing CYR-064, a potential treatment for hyposmia that demonstrated safety and efficacy in Phase 2 clinical trials.